+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Regenerative Medicine Market by Product Type, Material, Application and End user (Hospitals, Ambulatory Surgical Centers, and Others: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 257 Pages
  • March 2022
  • Region: Global
  • Allied Market Research
  • ID: 5578255
The regenerative medicine market was valued at $10,107.32 million in 2020, and is estimated to reach $83,196.72 million by 2030, growing at a CAGR of 23.4% from 2021 to 2030. Regenerative medicines are used to repair, replace, and regenerate tissues and organs affected by injury, disease, or natural aging process. These medicines restore the functionality of cells & tissues and are used in several degenerative disorders, such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. Stem cells are capable of proliferation and differentiation, which increase their importance in this field.



Increase in prevalence of musculoskeltal diseases, oncological disorders, and dental disorders is the major factor that contributes in the growth of the regenerative medicine market. Moreover, other factors that fuel the market growth include, increase in adoption of regenerative medicine products and technological advancement in stem cell-based therapies that have revolutionized the perspective research towards regenerative medicine. In addition, many companies are increasing their market presence, thereby expanding their business across new markets. For instance, in July 2021, Pharming Group N.V and Orchard collaborated for the development of commercialized OTL 105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Such factors have led to the growth of the regenerative medicine market.

Emergence of stem cell technology, untapped potential of nanotechnology, increase in prevalence of chronic diseases & trauma emergencies, advancement in monitoring devices and surgical technologies, rise in incidence of degenerative diseases, and shortage of organs for transplantation are major factors that drive the growth of the regenerative medicine market. Increase in focus on stem cells and growth in R&D activities in emerging economies are expected to supplement the market growth in the coming years. Developing nations are focused on technological advancements, which is expected to boost the market growth, globally. However, stringent government regulations, operational inefficiency, and high cost of treatment of regenerative medicines are estimated to hamper the growth of the regenerative medicine market.

Conversely, development of cost-effective therapeutics through large-scale production and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market. People, nowadays are becoming more health conscious, which compels them to maintain their health condition. Thus increasing the demand for regenerative medicine. This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the regenerative medicine market.

The regenerative medicine market is segmented on the basis of product type, material, application, and geography. On the basis of product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic.

On the basis of material, the market is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic.

On the basis of application, the market is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. On the basis of region, the market is analyzed across four regions, such as North America, Europe, Asia-Pacific, and LAMEA.

By material, the biologically derived material was the dominant segment in 2020, and is estimated to maintain this trend during the forecast period. The demand for genetically engineered material has increased due to their unique, such as promotion of cellular interactions, rise in proliferation, and differentiation of cells that facilitate self-assembly into directionally organized structures, and control the manipulation of cellular behavior.

By application the musculoskeletal application segment accounted for the largest share in 2020, whereas cardiovascular is expected to be the fastest-growing segment, registering a CAGR of 23.8% during the forecast period.

The use of regenerative medicine is highest in North America, particularly in the U.S., owing to increase in prevalence of chronic disorders, rise in demand for artificial organs due to organ failure, and presence of highly sophisticated healthcare infrastructure. Although the use of regenerative medicine in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase due to the presence of high unmet medical needs and constant improvement in the healthcare infrastructure to treat chronic disorders. In addition, countries such as China, India, Australia, and Japan contribute to the market growth owing to their large population and rise in demand for tissue-engineered and regenerative medicine products. These countries have varying demographics and cultural conditions, which highly influence their respective markets.

The key players operating in the global regenerative medicine market include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.), and CryoLife, Inc.

Other prominent players in the value chain include Shimadzu Recursion Pharmaceuticals, Inc., Baxter International, Inc., DePuy Synthes Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips N.V., Cloudmedx, Inc., and Bay Labs, Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global albumin market to identify the prevailing opportunities
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies
  • Comprehensive analysis of factors that drive and restrict the market growth is provided
  • Region- & country-wise analysis is provided to understand the market trends and dynamics

KEY MARKET SEGMENTS


By Product Type

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Small Molecule & Biologic

By Material

  • Synthetic Material
  • Biodegradable Synthetic Polymer
  • Scaffold
  • Artificial Vascular Graft Material
  • Hydrogel Material
  • Biologically Derived Material
  • Collagen
  • Xenogeneic Material
  • Genetically Engineered Material
  • Deoxyribonucleic Acid Transfection Vector
  • Genetically Manipulated Cell
  • Three-Dimensional Polymer Technology
  • Pharmaceutical
  • Small Molecule
  • Biologic

By Application

  • Cardiovascular
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Wound Healing
  • Ophthalmology
  • Neurology
  • Others

By End User

  • Hospitals
  • Ambulatory Surgical Center
  • Others

By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • 3 M
  • Athersys Inc
  • Cryo Life Inc
  • Integra Life Sciences
  • Isto Biologics
  • Medtronic Plc
  • Organogenesis
  • Stryker Corporation
  • US Stem Cell Inc
  • Zimmer Biomet Holdings Inc
Frequently Asked Questions about the Regenerative Medicine Market

What is the estimated value of the Regenerative Medicine Market?

The Regenerative Medicine Market was estimated to be valued at $10107.32 million in 2020.

What is the growth rate of the Regenerative Medicine Market?

The growth rate of the Regenerative Medicine Market is 23.5%, with an estimated value of $83196.72 million by 2030.

What is the forecasted size of the Regenerative Medicine Market?

The Regenerative Medicine Market is estimated to be worth $83196.72 million by 2030.

Who are the key companies in the Regenerative Medicine Market?

Key companies in the Regenerative Medicine Market include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.) and CryoLife, Inc..

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. High Adoption of Stem Cell Technology
3.4.1.2. Emerging Application of Nanotechnology
3.4.1.3. Increasing Prevalence of Chronic Diseases and Trauma Emergencies
3.4.1.4. Advancements in Medical Equipment Technologies
3.4.2. Restraints
3.4.2.1. Ethical Hurdles
3.4.2.2. Costly Treatment Associated With Regenerative Medicine
3.4.3. Opportunities
3.4.3.1. Lucrative Opportunities of Novel Stem Cell Technologies
3.4.3.2. Increase in Potential in Emerging Economies
3.4.3.3. Growth in Need of Regenerative Medicine in Organ Transplantation
Chapter 4: Regenerative Medicine Market, by Product Type
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Cell Therapy
4.2.1. Key Market Trends
4.2.2. Key Growth Factors and Growth Opportunities
4.2.3. Market Size and Forecast
4.3. Gene Therapy
4.3.1. Key Market Trends
4.3.2. Key Growth Factors and Growth Opportunities
4.3.3. Market Size and Forecast
4.4. Tissue Engineering
4.4.1. Key Market Trends
4.4.2. Key Growth Factors and Opportunities
4.4.3. Market Size and Forecast
4.5. Small Molecules and Biologic
4.5.1. Key Market Trends
4.5.2. Key Growth Factors and Opportunities
4.5.3. Market Size and Forecast
Chapter 5: Regenerative Medicine Market, by Material
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Synthetic Material
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Size and Forecast, by Type
5.2.3. Biodegradable Synthetic Polymer
5.2.3.1. Market Size and Forecast
5.2.4. Scaffold
5.2.4.1. Market Size and Forecast
5.2.5. Artificial Vascular Graft Material
5.2.5.1. Market Size and Forecast
5.2.6. Hydrogel Material
5.2.6.1. Market Size and Forecast
5.3. Biologically Derived Material
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Size and Forecast, by Type
5.3.3. Collagen
5.3.3.1. Market Size and Forecast
5.3.4. Xenogeneic Material
5.3.4.1. Market Size and Forecast
5.4. Genetically Engineered Material
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Size and Forecast, by Type
5.4.3. Deoxyribonucleic Acid Transfection Vector
5.4.3.1. Market Size and Forecast
5.4.4. Genetically Manipulated Cell
5.4.4.1. Market Size and Forecast
5.4.5. Three-Dimensional Polymer Technology
5.4.5.1. Market Size and Forecast
5.4.6. Transgenics
5.4.6.1. Market Size and Forecast
5.4.7. Fibroblast
5.4.7.1. Market Size and Forecast
5.4.8. Neural Stem Cell
5.4.8.1. Market Size and Forecast
5.4.9. Gene-Activated Matrices
5.4.9.1. Market Size and Forecast
5.5. Pharmaceutical
5.5.1. Market Size and Forecast, by Region
5.5.2. Market Size and Forecast, by Type
5.5.3. Small Molecule
5.5.3.1. Market Size and Forecast
5.5.4. Biologic
5.5.4.1. Market Size and Forecast
Chapter 6: Regenerative Medicine Market, by Application
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Cardiovascular
6.2.1. Market Size and Forecast
6.3. Oncology
6.3.1. Market Size and Forecast
6.4. Dermatology
6.4.1. Market Size and Forecast
6.5. Musculoskeletal
6.5.1. Market Size and Forecast
6.6. Wound Healing
6.6.1. Market Size and Forecast
6.7. Ophthalmology
6.7.1. Market Size and Forecast
6.8. Neurology
6.8.1. Market Size and Forecast
6.9. Others
6.9.1. Market Size and Forecast
Chapter 7: Regenerative Medicine Market, by Region
7.1. Overview
7.1.1. Market Size and Forecast
7.2. North America
7.2.1. Key Market Trends
7.2.2. Key Growth Factors and Opportunities
7.2.3. Market Size and Forecast, by Product Type
7.2.4. Market Size and Forecast, by Material
7.2.5. Market Size and Forecast, by Application
7.2.6. Market Size and Forecast, by Country
7.2.6.1. U. S. Market Size and Forecast
7.2.6.2. Canada Market Size and Forecast
7.2.6.3. Mexico Market Size and Forecast
7.3. Europe
7.3.1. Key Market Trends
7.3.2. Key Growth Factors and Opportunities
7.3.3. Market Size and Forecast, by Product Type
7.3.4. Market Size and Forecast, by Material
7.3.5. Market Size and Forecast, by Application
7.3.6. Market Size and Forecast, by Country
7.3.6.1. Germany Market Size and Forecast
7.3.6.2. France Market Size and Forecast
7.3.6.3. Uk Market Size and Forecast
7.3.6.4. Italy Market Size and Forecast
7.3.6.5. Spain Market Size and Forecast
7.3.6.6. Russia Market Size and Forecast
7.3.6.7. Rest of Europe Market Size and Forecast
7.4. Asia-Pacific
7.4.1. Key Market Trends
7.4.2. Key Growth Factors and Opportunities
7.4.4. Market Size and Forecast, by Material
7.4.5. Market Size and Forecast, by Application
7.4.6. Market Size and Forecast, by Country
7.4.6.1. Japan Market Size and Forecast
7.4.6.2. China Market Size and Forecast
7.4.6.3. Australia Market Size and Forecast
7.4.6.4. India Market Size and Forecast
7.4.6.5. South Korea Market Size and Forecast
7.4.6.6. Taiwan Market Size and Forecast
7.4.6.7. Rest of Asia-Pacific Market Size and Forecast
7.5. Lamea
7.5.1. Key Market Trends
7.5.2. Key Growth Factors and Opportunities
7.5.3. Market Size and Forecast, by Product Type
7.5.4. Market Size and Forecast, by Material
7.5.5. Market Size and Forecast, by Application
7.5.6. Market Size and Forecast, by Country
7.5.6.1. Brazil Market Size and Forecast
7.5.6.2. Turkey Market Size and Forecast
7.5.6.3. Venezuela Market Size and Forecast
7.5.6.4. Saudi Arabia Market Size and Forecast
7.5.6.5. South Africa Market Size and Forecast
7.5.6.6. Rest of LAMEA Market Size and Forecast
Chapter 8: Company Profiles
8.1.3M Company
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Athersys, Inc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Product Portfolio
8.2.4. Business Performance
8.3. Cryolife, Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Integra Lifesciences Corporation
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves and Developments
8.5. Isto Biologics (Isto Biologics Medical Systems, Inc.)
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Product Portfolio
8.6. Medtronic plc
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Organogenesis Inc.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Product Portfolio
8.8. Stryker Corporation
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. U. S. Stem Cell, Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
.
8.9.3. Product Portfolio
8.9.4. Business Performance
8.10. Zimmer Biomet Holdings, Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves and Developments
List of Tables
Table 01. Unintentional Injuries Facts (2013)
Table 02. Global Regenerative Medicine Market, by Product Type, 2016–2023 ($Million)
Table 03. Regenerative Medicine Market for Cell Therapy, by Region, 2016–2023 ($Million)
Table 04. Regenerative Medicine Market for Gene Therapy, by Region, 2016–2023 ($Million)
Table 05. Regenerative Medicine Market for Tissue Engineering, by Region, 2016–2023 ($Million)
Table 06. Regenerative Medicine Market for Small Molecules & Biologics, by Region, 2016–2023 ($Million)
Table 07. Global Regenerative Medicine Market, by Material, 2016–2023 ($Million)
Table 08. Regenerative Medicine Market for Synthetic Material, by Region, 2016–2023 ($Million)
Table 09. Regenerative Medicine Market for Synthetic Material, by Type, 2016–2023 ($Million)
Table 10. Classification of Biodegradable Polymers
Table 11. Regenerative Medicine Market for Biodegradable Synthetic Polymer, by Region, 2016–2023 ($Million)
Table 12. Classification of Biodegradable Polymers
Table 13. Regenerative Medicine Market for Scaffold, by Region, 2016–2023 ($Million)
Table 14. Regenerative Medicine Market for Artificial Vascular Graft Materials, by Region, 2016–2023 ($Million)
Table 15. Regenerative Medicine Market for Hydrogel Material, by Region, 2016–2023 ($Million)
Table 16. Regenerative Medicine Market for Biologically Derived Materials, by Region, 2016–2023 ($Million)
Table 17. Regenerative Medicine Market for Biologically Derived Materials, by Type, 2016–2023 ($Million)
Table 18. Regenerative Medicine Market for Collagen Material, by Region, 2016–2023 ($Million)
Table 19. Regenerative Medicine Market for Xenogeneic Material, by Region, 2016–2023 ($Million)
Table 20. Regenerative Medicine Market for Genetically Engineered Materials, by Region, 2016–2023 ($Million)
Table 21. Regenerative Medicine Market for Genetically Engineered Materials, by Type, 2016–2023 ($Million)
Table 22. Regenerative Medicine Market for Deoxyribonucleic Acid Transfection Vectors, by Region, 2016–2023 ($Million)
Table 23. Regenerative Medicine Market for Genetically Manipulated Cells, by Region, 2016–2023 ($Million)
Table 24. Regenerative Medicine Market for Three-Dimensional Polymer Technology, by Region, 2016–2023 ($Million)
Table 25. Regenerative Medicine Market for Transgenics, by Region, 2016–2023 ($Million)
Table 26. Regenerative Medicine Market for Fibroblasts, by Region, 2016–2023 ($Million)
Table 27. Regenerative Medicine Market for Neural Stem Cells, by Region, 2016–2023 ($Million)
Table 28. Regenerative Medicine Market for Gene-Activated Matrices, by Region, 2016–2023 ($Million)
Table 29. Regenerative Medicine Market for Pharmaceuticals, by Region, 2016–2023 ($Million)
Table 30. Regenerative Medicine Market for Pharmaceuticals, by Type, 2016–2023 ($Million)
Table 31. Regenerative Medicine Market for Small Molecules, by Region, 2016–2023 ($Million)
Table 32. Regenerative Medicine Market for Biologics, by Region, 2016–2023 ($Million)
Table 33. Global Regenerative Medicine Market, by Application, 2016–2023 ($Million)
Table 34. Regenerative Medicine Market for Cardiovascular, by Region, 2016–2023 ($Million)
Table 35. Regenerative Medicine Market for Oncology, by Region, 2016–2023 ($Million)
Table 36. Statistics for Skin Damage Medical Conditions in the U.S And Worldwide, 2011
Table 37. List of Acellular Skin Tissue-Engineered Products in the Market
Table 38. List of Cellular Skin Tissue-Engineered Products in the Market
Table 39. Regenerative Medicine Market for Dermatology, by Region, 2016–2023 ($Million)
Table 40. Statistics for Bone Damage and Related Diseases, 2011
Table 41. Statistics for Cartilage Damage Worldwide
Table 42. Regenerative Medicine Market for Musculoskeletal, by Region, 2016–2023 ($Million)
Table 43. Regenerative Medicine Market for Wound Healing, by Region, 2016–2023 ($Million)
Table 44. Regenerative Medicine Market for Ophthalmology, by Region, 2016–2023 ($Million)
Table 45. Regenerative Medicine Market for Neurology, by Region, 2016–2023 ($Million)
Table 46. Regenerative Medicine Market for Other Application, by Region, 2016–2023 ($Million)
Table 47. Regenerative Medicine Market, by Region, 2016–2023 ($Million)
Table 48. North America Regenerative Medicine Market, by Product Type, 2016–2023 ($Million)
Table 49. North America Regenerative Medicine Market, by Material, 2016–2023 ($Million)
Table 50. North America Regenerative Medicine Market for Synthetic Material, 2016–2023 ($Million)
Table 51. North America Regenerative Medicine Market for Biologically Derived Material, 2016–2023 ($Million)
Table 52. North America Regenerative Medicine Market for Genetically Engineered Material, 2016–2023 ($Million)
Table 53. North America Regenerative Medicine Market for Pharmaceuticals, 2016–2023 ($Million)
Table 54. North America Regenerative Medicine Market, by Application, 2016–2023 ($Million)
Table 55. North America Regenerative Medicine Market, by Country, 2016–2023 ($Million)
Table 56. Europe Regenerative Medicine Market, by Product Type, 2016–2023 ($Million)
Table 57. Europe Regenerative Medicine Market, by Material, 2016–2023 ($Million)
Table 58. Europe Regenerative Medicine Market for Synthetic Material, 2016–2023 ($Million)
Table 59. Europe Regenerative Medicine Market for Biologically Derived Material, 2016–2023 ($Million)
Table 60. Europe Regenerative Medicine Market for Genetically Engineered Material, 2016–2023 ($Million)
Table 61. Europe Regenerative Medicine Market for Pharmaceuticals, 2016–2023 ($Million)
Table 62. Europe Regenerative Medicine Market, by Application, 2016–2023 ($Million)
Table 63. Europe Regenerative Medicine Market, by Country, 2016–2023 ($Million)
Table 64. Asia-Pacific Regenerative Medicine Market, by Product Type, 2016–2023 ($Million)
Table 65. Asia-Pacific Regenerative Medicine Market, by Material, 2016–2023 ($Million)
Table 66. Asia-Pacific Regenerative Medicine Market for Synthetic Material, 2016–2023 ($Million)
Table 67. Asia-Pacific Regenerative Medicine Market for Biologically Derived Material, 2016–2023 ($Million)
Table 68. Asia-Pacific Regenerative Medicine Market for Genetically Engineered Material, 2016–2023 ($Million)
Table 69. Asia-Pacific Regenerative Medicine Market for Pharmaceuticals, 2016–2023 ($Million)
Table 70. Asia-Pacific Regenerative Medicine Market, by Application, 2016–2023 ($Million)
Table 71. Asia-Pacific Regenerative Medicine Market, by Country, 2016–2023 ($Million)
Table 72. Lamea Regenerative Medicine Market, by Product Type, 2016–2023 ($Million)
Table 73. Lamea Regenerative Medicine Market, by Material, 2016–2023 ($Million)
Table 74. Lamea Regenerative Medicine Market for Synthetic Material, 2016–2023 ($Million)
Table 75. Lamea Regenerative Medicine Market for Biologically Derived Material, 2016–2023 ($Million)
Table 76. Lamea Regenerative Medicine Market for Genetically Engineered Material, 2016–2023 ($Million)
Table 77. Lamea Regenerative Medicine Market for Pharmaceuticals, 2016–2023 ($Million)
Table 78. Lamea Regenerative Medicine Market, by Application, 2016–2023 ($Million)
Table 79. Lamea Regenerative Medicine Market, by Country, 2016–2023 ($Million)
Table 80. 3M: Company Snapshot
Table 81. 3M: Operating Segments
Table 82. 3M: Product Portfolio
Table 83. Athersys: Company Snapshot
Table 84. Athersys: Product Portfolio
Table 85. Cryolife: Company Snapshot
Table 86. Cryolife: Product Categories
Table 87. Cryolife: Product Portfolio
Table 88. Integra Lifesciences: Company Snapshot
Table 89. Integra Lifesciences: Operating Segments
Table 90. Integra Life Sciences: Product Portfolio
Table 91. Isto Biologics: Company Snapshot
Table 92. Isto: Product Portfolio
Table 93. Medtronic: Company Snapshot
Table 94. Medtronic: Product Categories
Table 95. Medtronic: Product Portfolio
Table 96. Organogenesis: Company Snapshot
Table 97. Organogenesis: Product Portfolio
Table 98. Stryker: Company Snapshot
Table 99. Stryker: Operating Segments
Table 100. Stryker: Product Portfolio
Table 101. Us Stem Cell: Company Snapshot
Table 102. Us Stem Cell: Product Portfolio
Table 103. Zimmer Biomet: Company Snapshot
Table 104. Zimmer Biomet: Operating Segments
Table 105. Zimmer Biomet: Product Portfolio
List of Figures
Figure 01. Global Regenerative Medicine Market Segmentation
Figure 02. Top Investment Pockets
Figure 03. Top Winning Strategies, by Year, 2016–2018*
Figure 04. Top Winning Strategies, by Development, 2016–2018* (%)
Figure 05. Top Winning Strategies, by Company, 2016–2018*
Figure 06. Low Bargaining Power of Buyers
Figure 07. Moderate Bargaining Power of Suppliers
Figure 08. High Threat of New Entrants
Figure 09. Low Threat of Substitution
Figure 10. High Competitive Rivalry
Figure 11. U. S. Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 12. Canada Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 13. Mexico Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 14. Germany Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 15. France Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 16. Uk Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 17. Italy Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 18. Spain Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 19. Russia Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 20. Rest of Europe Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 21. Japan Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 22. China Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 23. Australia Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 24. India Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 25. South Korea Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 26. Taiwan Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 27. Rest of Asia-Pacific Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 28. Brazil Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 29. Turkey Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 30. Venezuela Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 31. Saudi Arabia Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 32. South Africa Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 33. Rest of LAMEA Regenerative Medicine Market, 2016-2023 ($ Million)
Figure 34. 3M: Revenue, 2018–2020 ($ Million)
Figure 35. 3M: Revenue Share by Segment, 2020 (%)
Figure 36. 3M: Revenue Share by Region, 2020 (%)
Figure 37. Athersys: Revenue, 2018–2020 ($ Million)
Figure 38. Athersys: Revenue Share by Segment, 2020 (%)
Figure 39. Cryolife: Revenue, 2018–2020 ($ Million)
Figure 40. Cryolife: Revenue Share by Segment, 2020 (%)
Figure 41. Cryolife: Revenue Share by Region, 2020 (%)
Figure 42. Integra Lifesciences: Revenue, 2018–2020 ($ Million)
Figure 43. Integra Lifesciences: Revenue Share by Segment, 2020 (%)
Figure 44. Integra Lifesciences: Revenue Share by Region, 2020 (%)
Figure 45. Medtronic: Net Sales, 2018–2020 ($ Million)
Figure 46. Medtronic: Revenue Share by Segment 2020 (%)
Figure 47. Medtronic: Revenue Share by Region 2020 (%)
Figure 48. Stryker: Revenue, 2018–2020 ($ Million)
Figure 49. Stryker: Revenue Share by Segment, 2020 (%)
Figure 50. Stryker: Revenue Share by Region, 2020 (%)
Figure 51. Us Stem Cell: Revenue, 2018–2020 ($ Million)
Figure 52. Us Stem Cell: Revenue Share by Segment, 2020 (%)
Figure 53. Zimmer Biomet: Revenue, 2018–2020 ($ Million)
Figure 54. Zimmer Biomet: Revenue Share by Segment, 2020 (%)
Figure 55. Zimmer Biomet: Revenue Share by Region, 2020 (%)

Executive Summary

According to a new report titled, “Regenerative Medicine Market by Type, Material, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021–2030,” the regenerative medicine market size was valued at $10,107.32 million in 2020, and is estimated to reach $83,196.72 million by 2030, growing at a CAGR of 23.4% from 2021 to 2030.

Regenerative medicine is a process of replacing human cells, tissues or organs to restore or establish normal function. It is field that brings together experts in biology, chemistry, genetics and medicine. This is a promising field which working to restore structure and function of damaged tissues and organs. It includes cell therapy involves the use of cellular materials such as stem cells, autologous cells, xenogeneic cells, and others, for the therapeutic treatment of patients. Cell therapy is used to replace damaged cells, deliver therapies to target tissues/organs, stimulate self-healing, and various other applications in regenerative medicine.

The major factors boosting the regenerative medicine market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, increase in incidence of degenerative diseases and shortage of organs for transplantation are expected to boost the growth of the market. The prominent potential of regenerative medicine to replace, repair, and regenerate damaged tissues and organs has fueled the market growth. In addition, technological advancements in regenerative medicine production and advancement in the stem cell therapy procedures propel the growth of the market. Rise in prevalence of musculoskeletal diseases and increase in dermatological treatments propel the growth of the market. Moreover, utilization of nanomaterial’s in wound care, drug delivery, and immunomodulation has opened growth avenues for the regenerative medicine market.

However, stringent regulations, operational inefficiency, and high cost of regenerative medicine treatment are key factors that hinder the market growth. Furthermore, advancements in stem cell technology and increase in R&D activities in the emerging economies are expected to fuel the market growth during the forecast period. Developed nations have adopted technological advancements in tissue engineering and regenerative medicine sectors, which help in the expansion of the global market.

Moreover, rise in development of pharmaceutical and medical device industries and improvement in healthcare spending are anticipated to drive the growth of the regenerative medicine market. In addition, increase in demand for regenerative medicine led to development of innovative technologies in the healthcare sector, thereby propelling growth of the market.

Moreover, initiatives taken by governments for development of advanced stem cell therapies and development of the healthcare sector for manufacturing of regenerative medicine are the key factors that boost growth of the market. Furthermore, surge in geriatric population, who are more vulnerable to chronic disease, propels the market growth.

The regenerative medicine market is segmented on the basis of type, material, application, end user, and region. On the basis of type, the market is divided into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. The XXX segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in prevalence of cancer cases and advancements in R&D activities in pharmaceutical & medical device industries.

By material, the market is fragmented into synthetic material, biologically derived material, genetically engineered material, and pharmaceuticals.

By application, the market is classified into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. The xxx segment acquired top position in the market in 2020, and this trend is expected to continue during the forecast period, owing to large number of regenerative medicine products offered by key players and increase in demand for cell therapies for treatment of various disorders.

By end user, the market is classified into hospitals & clinics, ambulatory surgical centers, and others. The XXX segment led the market in 2020, and this trend is expected to continue during the forecast period, owing to advancements in technology in the healthcare sector.

North America accounted for a majority of the global regenerative medicine market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to high capital investment, high disposable income of patients, numerous clinical studies, and favorable government policies for the commercialization of tissue engineering and regenerative medicine products, increase in number of approvals for regenerative medicine products, presence of key players, and development in technology for healthcare in the region. Asia-Pacific is anticipated to witness lucrative growth, due to the improving healthcare infrastructure and healthcare expenditures in the emerging markets, such as India and China, to overcome the unmet medical needs in these countries.

Key Findings Of The Study


  • By type, the XXX segment was the highest contributor to the market in 2020
  • On the basis of application type, the XXX segment dominated the regenerative medicine market in 2020, and is expected to continue this trend during the forecast period
  • Depending on end user, the XXX segment was the highest contributor to the market in 2020
  • Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period

Companies Mentioned

  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
  • Medtronic Plc.
  • Athersys, Inc.
  • U.S. Stem Cell, Inc. (Bioheart, Inc.)
  • Organogenesis, Inc. (Advanced Biohealing)
  • Integra Lifesciences Holdings Corporation
  • Acelity Holdings, Inc.
  • Isto Biologics (Isto Biologics Medical Systems, Inc.)
  • CryoLife, Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...